Market News & Trends
XOMA Expands its Commercial Royalty & Milestone Portfolio With DSUVIA Acquisition
XOMA Corporation recently announced it has acquired an economic interest in DSUVIA (sufentanil sublingual tablet) from Talphera, Inc., for $8 million. DSUVIA was approved in…
Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development & Manufacturing Organization
Kindeva Drug Delivery recently announced it has acquired Summit Biosciences Inc., an intranasal drug delivery contract development and manufacturing organization, from its founding….
Vivtex & AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases
Vivtex Corporation and AI Proteins, Inc. recently announced they have entered a strategic R&D collaboration to develop novel, oral biologic therapies for inflammatory diseases. The partners…
Credence MedSystems Announces a Significant Milestone Toward Scaling Manufacturing Capabilties
Credence MedSystems recently announced it has successfully completed Factory Acceptance Testing (FAT) for production of its Companion® injection device platform on the company’s new Clinical Assembly Line…..
Orphan Drug Designation Granted to PTX-252 by FDA for the Treatment of Acute Myeloid Leukaemia
Hyloris Pharmaceuticals SA recently announced the US FDA has granted Orphan Drug Designation to PTX-252 for the treatment of Acute Myeloid Leukaemia (AML). This product…
Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith for $210 Million in Transaction to Fuel Global Expansion
Bora Pharmaceuticals Co., Ltd. recently announced its Board of Directors has approved the acquisition of Upsher-Smith Laboratories, Inc., a generics manufacturer based in Minnesota, US, from shareholders, Sawai….
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients With Glioblastoma Multiforme
Lisata Therapeutics, Inc. recently announced treatment of the first patient in a Phase 2a trial evaluating LSTA1 in patients with newly diagnosed glioblastoma multiforme (GBM).…
Vetter Becomes Member of the German Association of Research-Based Pharmaceutical Companies (vfa)
Vetter has joined the German Association of Research-Based Pharmaceutical Companies (vfa) as an associate member. With this membership, the vfa recognizes the significant role that…
SPRIM Global Funds Prota's Promising Peanut Allergy Treatment That Results in Remission, Not Just Desensitization
Prota Therapeutics recently announced financing of $21 million in equity and debt financing. The round, led by Singapore-based SPRIM Global Investments (SGI), will help the…
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia & Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
Coya Therapeutics, Inc. recently announced it is expanding its pipeline in neurodegenerative conditions for COYA 302 beyond ALS to include frontotemporal dementia (FTD) and Parkinson’s…
Abzena Launches AbZelect Platforms for Improving Cell Line Development Efficiency on the Pathway to IND
Abzena has launched AbZelect and AbZelectPRO cell line development (CLD) platforms for accelerating the generation of production cell lines for manufacture of antibodies and recombinant proteins. The platforms will….
PolTREG Receives US Patent Office Notice of Allowance for Treg Cell Therapy to Treat Type-1 Diabetes
PolTREG S.A. recently announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO), covering the manufacturing of T-regulatory cells…
Intravacc Awarded CARB-X Funding to Develop Vaccine That Prevents Gonorrhea Infections
Intravacc recently announced it has been awarded a funding that may total $633K from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) a global non-profit organization, for the….
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure With Defence Research & Development Canada
Revive Therapeutics Ltd. recently announced an update on its project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada –…
Emergex Announces R&D Collaboration With DEKA Research & Development Corp. for Assessment of Emergex’s Immunotherapeutic Candidates With DEKA’s Intradermal Therapeutic Applicator
Emergex Vaccines Holding Limited recently announced it has entered into an agreement with DEKA to assess the compatibility of Emergex’s immunotherapeutic candidates with the DEKA Intradermal Therapeutic Applicator…..
Anavex Life Sciences Announces US Phase 2 Clinical Trial of ANAVEX3-71 in Schizophrenia
Anavex Life Sciences Corp. recently announced the initiation of the US FDA cleared placebo-controlled Phase 2 trial of ANAVEX3-71 for the treatment of schizophrenia, which…
Santhera Launches Vamorolone in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy
Santhera Pharmaceuticals recently announced the launch of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older,…
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
ExeVir Bio recently announced new data demonstrating that its antibodies are highly potent in neutralizing currently circulating COVID-19 Omicron variants. All authorized SARS-CoV-2 therapeutic antibodies…
Henlius & Sermonix Announce Strategic Collaboration & Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. recently announced a strategic collaboration agreement in which Henlius will receive exclusive rights to develop, manufacture, and…
Contract Packaging Predicted to See High Growth in 2024 Ahead of Pharmapack Europe
The outlook for pharma services in 2024 is continuing to improve, with 94% of the industry either “moderately positive” (37%) or “highly positive” (37%) on growth for contract packaging in….
